BACKGROUND: Efforts to improve the quality of care for patients with cardiovascular disease frequently target the decrease of physician-level performance variability. We assessed how variability in providing β-blockers to ambulatory postmyocardial infarction (MI) patients was influenced by physician and patient level characteristics. METHODS AND RESULTS: β-Blocker prescription and patient characteristics were abstracted from charts of post-MI patients treated by 133 primary care physicians between 2003 and 2007 and linked to physician and practice characteristics. Associations of β-blocker prescription with physician- and patient-level characteristics were examined using mixed-effects models, with physician-level effects as random. Mean physician-specific predicted probabilities and the intraclass correlations, which assessed the proportion of variance explainable at the physician level, were estimated. Of 1901 patients without major contraindication, 69.1% (range across physicians, 20% to 100%) were prescribed β-blockers. Prescription varied with comorbidity from 78.3% in patients with chronic kidney disease to 54.7% for patients with stroke. Although physician characteristics such as older physician age, group practice, and rural location were each positively associated with β-blocker prescription, physician factors accounted for only 5% to 8% of the variance in β-blocker prescription; the preponderance of the variance, 92% to 95%, was at the patient level. The mean physician-specific probability of β-blocker prescription (95% confidence interval) in the fully adjusted model was 63% (61% to 65%). CONCLUSIONS: β-Blocker prescription rates were surprisingly low. The contribution of physician factors to overall variability in β-blocker prescription, however, was limited. Increasing evidence-based use of β-blockers may not be accomplished by focusing mostly on differential performance across physicians.
BACKGROUND: Efforts to improve the quality of care for patients with cardiovascular disease frequently target the decrease of physician-level performance variability. We assessed how variability in providing β-blockers to ambulatory postmyocardial infarction (MI) patients was influenced by physician and patient level characteristics. METHODS AND RESULTS: β-Blocker prescription and patient characteristics were abstracted from charts of post-MI patients treated by 133 primary care physicians between 2003 and 2007 and linked to physician and practice characteristics. Associations of β-blocker prescription with physician- and patient-level characteristics were examined using mixed-effects models, with physician-level effects as random. Mean physician-specific predicted probabilities and the intraclass correlations, which assessed the proportion of variance explainable at the physician level, were estimated. Of 1901 patients without major contraindication, 69.1% (range across physicians, 20% to 100%) were prescribed β-blockers. Prescription varied with comorbidity from 78.3% in patients with chronic kidney disease to 54.7% for patients with stroke. Although physician characteristics such as older physician age, group practice, and rural location were each positively associated with β-blocker prescription, physician factors accounted for only 5% to 8% of the variance in β-blocker prescription; the preponderance of the variance, 92% to 95%, was at the patient level. The mean physician-specific probability of β-blocker prescription (95% confidence interval) in the fully adjusted model was 63% (61% to 65%). CONCLUSIONS: β-Blocker prescription rates were surprisingly low. The contribution of physician factors to overall variability in β-blocker prescription, however, was limited. Increasing evidence-based use of β-blockers may not be accomplished by focusing mostly on differential performance across physicians.
Authors: Stacie L Daugherty; P Michael Ho; John A Spertus; Philip G Jones; Richard G Bach; Harlan M Krumholz; Eric D Peterson; John S Rumsfeld; Frederick A Masoudi Journal: Arch Intern Med Date: 2008-03-10
Authors: Sebastian Schneeweiss; Amanda R Patrick; Malcolm Maclure; Colin R Dormuth; Robert J Glynn Journal: Circulation Date: 2007-04-09 Impact factor: 29.690
Authors: Patrick J O'Connor; William A Rush; Gestur Davidson; Thomas A Louis; Leif I Solberg; Lauren Crain; Paul E Johnson; Robin R Whitebird Journal: Prev Chronic Dis Date: 2007-12-15 Impact factor: 2.830
Authors: Leah M Goeres; Allison Gille; Jon P Furuno; Deniz Erten-Lyons; Daniel M Hartung; James F Calvert; Sharia M Ahmed; David S H Lee Journal: J Rural Health Date: 2015-10-30 Impact factor: 4.333
Authors: Ellen Funkhouser; Deborah A Levine; Joe K Gerald; Thomas K Houston; Nancy K Johnson; Jeroan J Allison; Catarina I Kiefe Journal: Implement Sci Date: 2011-09-09 Impact factor: 7.327
Authors: Gaetanne K Murphy; Finlay A McAlister; Daniala L Weir; Lisa Tjosvold; Dean T Eurich Journal: BMC Public Health Date: 2014-06-02 Impact factor: 3.295